Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Ledergerber

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|November 4, 2000
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort StudyO T Rutschmann, P L Vernazza, H C Bucher, et al.
JAMA|December 22, 1999
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort StudyB Ledergerber, M Egger, V Erard, et al.
British Journal of Cancer|November 16, 2006
Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort StudyS Franceschi, J Polesel, M Rickenbach, et al.
Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 1, 1996
Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study GroupP Sudre, B J Hirschel, J M Gatell, et al.
Lancet (London, England)|December 16, 2000
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort StudyG Greub, B Ledergerber, M Battegay, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 9, 1997
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study GroupJ D Lundgren, A N Phillips, S Vella, et al.
HIV Medicine|May 8, 2019
Why do sub-Saharan Africans present late for HIV care in Switzerland?A Hachfeld, K Darling, A Calmy, et al.
HIV Medicine|July 3, 2015
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptakeV Schaerer, S Haubitz, H Kovari, et al.
The Journal of Antimicrobial Chemotherapy|May 14, 2014
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individualsM Arab-Alameddine, R Lubomirov, A Fayet-Mello, et al.
The Journal of Antimicrobial Chemotherapy|January 22, 2017
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patientsC Sekaggya-Wiltshire, A von Braun, A U Scherrer, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|November 4, 2000
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort StudyO T Rutschmann, P L Vernazza, H C Bucher, et al.
JAMA|December 22, 1999
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort StudyB Ledergerber, M Egger, V Erard, et al.
British Journal of Cancer|November 16, 2006
Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort StudyS Franceschi, J Polesel, M Rickenbach, et al.
Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 1, 1996
Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study GroupP Sudre, B J Hirschel, J M Gatell, et al.
Lancet (London, England)|December 16, 2000
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort StudyG Greub, B Ledergerber, M Battegay, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 9, 1997
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study GroupJ D Lundgren, A N Phillips, S Vella, et al.
HIV Medicine|May 8, 2019
Why do sub-Saharan Africans present late for HIV care in Switzerland?A Hachfeld, K Darling, A Calmy, et al.
HIV Medicine|July 3, 2015
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptakeV Schaerer, S Haubitz, H Kovari, et al.
The Journal of Antimicrobial Chemotherapy|May 14, 2014
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individualsM Arab-Alameddine, R Lubomirov, A Fayet-Mello, et al.
The Journal of Antimicrobial Chemotherapy|January 22, 2017
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patientsC Sekaggya-Wiltshire, A von Braun, A U Scherrer, et al.
Pageof 12